a defined clinical course and a biology that is distinct from the other forms of AML. Morphologically, the most common form of APL can have a characteristic appearance, because the bone marrow is effaced by heavily granulated cells with folded, twisted nuclei. Biologically, the cytogenetic changes define the syndrome, and the molecular consequences of the chromosomal changes found in APL play a critical role in leukemogenesis.
a defined clinical course and a biology that is distinct from the other forms of AML. Morphologically, the most common form of APL can have a characteristic appearance, because the bone marrow is effaced by heavily granulated cells with folded, twisted nuclei. Biologically, the cytogenetic changes define the syndrome, and the molecular consequences of the chromosomal changes found in APL play a critical role in leukemogenesis. [1] APL [AML with t(15;17)(q22;q21)] is an acute myeloid leukemia, in which abnormal promyelocytic predominate. Both hypergranular or "typical" APL and microgranular (hypogranular) types exist. [2] Characteristic cells containing bundles of Auer rods (faggots) randomly distributed in the cytoplasm are almost invariably present in the bone marrow and sometimes in the peripheral blood. The cytoplasm of the cells that contain faggots is often clear and pale staining but
Introduction
Acute myelogenous leukemia (AML) is a malignant disorder of the bone marrow, where a maturational arrest in blood cell progenitors results in the failure of normal hematopoiesis. Acute promyelocytic leukemia (APL) is a subtype of AML with may also contain azurophil granules. The cytochemistry of both forms of M3 shows characteristic strong positivity for peroxidase or Sudan Black B and for chloroacetate esterase. The bundles of Auer rods are recognized easily with the latter stains but not the former.
A unique chromosomal translocation that defines M3 is t(15;17)(q22;q21). [3] This translocation results in the fusion of the promyelocytic leukemia gene "PML" and the retinoic acid receptor (RARα) gene. [4] With the use of conventional cytogenetics, the t(15;17) can be detected in majority of the cases with M3 at the time of diagnosis. Probably, all cases can be detected by either the application of fluorescence in situ hybridization (FISH) [5, 6] or by molecular analysis. [7, 8] In addition, Gallagher et al. [9] have described molecular variants of the fusion product-the long or L form (PML exon 6 to RARα exon 2; the variable or V form), exon 6 coding nucleotides to RARα exon 2, and the short or S form (PML exon 3 to RARα exon 2). Neither of the two major types (S and L forms) have a prognostic significance although the microgranular variety of M3 is more commonly seen with the S form. [10] In 1993, Chen et al. [11] described a fusion product between a novel zinc finger gene and the retinoic acid receptor with t(11;17)(q23;q21) in a patient with APL. Licht et al. [12] reported on five additional "M3-like" cases with morphology "in a small morphologic spectrum with features intermediate between M2 and classical M3 AML." The gene fusion product was referred to as promyelocytic leukemia zinc finger (PLZF)−RARα. None of the patients responded to all-trans retinoic acid (ATRA). The published photomicrographs reveal myeloblasts with heavy granulations but no faggot cells or nuclear features of M3, although the report mentions "faggots" and/or Auer rods in three of four cases.
In 1996, [13] a second novel translocation t(11;17)(q13;q21) was identified in a survey of patients diagnosed morphologically as "APL" (FAB M3). The fusion product described was nuclear mitotic apparatus (NuMA)−RARα. Finally, a different translocation, t(5;17)(q32;q12) associated with the nucleophosmin (NPM)−RARα fusion gene product was described. [14] In a subsequent article, Redner et al. [15] demonstrated maturation to neutrophils in cell culture treated with ATRA.
To further clarify this important observation, members of the FAB Co-operative Group held a workshop in June 1996 in London, UK. In addition to the FAB members, Dr Cheryl Willman, Professor of Pathology at the University of New Mexico Cancer Center and Chair of the Leukemia Biology Committee of the Southwest Oncology Group (SWOG), attended.
Materials and Methods
Cases of both classical M3 and those with different cytogenetic findings but resembling M3 were assembled. Romanowsky-stained slides were examined after being coded. The blasts were examined for size, chromatin pattern, nuclear features, cytoplasmic features, and the presence of Auer rods. On the basis of morphologic features, the reviewers gave an impression (AML-M3 or AML-M3-like). The cytochemical (Sudan Black and periodic acid Schiff), immunophenotypic, karyotypic, and molecular features (if available) were also reviewed. On the basis of morphological assessment, cases were diagnosed as classical M3, M3 variant, and not M3.
Flow cytometric data for the cases were reviewed retrospectively. Analysis was performed initially on the periph eral blood and/or bone marrow aspirate specimens. Antibody combinations selected for review included CD45, CD34, CD14, CD13, CD33, HLA-DR (Becton Dickinson), and CD56 (Coulter).
For karyotype analysis, cells from unstimulated peripheral blood or bone marrow aspirate specimens were arrested at metaphase with colchicine. Chromosomes were stained by the G-banding method. The chromosome number was determined by microscopic analysis, and the cells were examined for the presence or absence of detectable structural rearrangements. Karyotypes were prepared from computer-assisted images of the metaphases.
FISH was also performed using a PML/RARα dual-color translocation probe.
A total of 238 cases were reviewed over a period of 30 months. Molecular analysis by FISH was performed in 160 cases for further confirmation.
Result
The patients in this study included 132 male subjects and 106 female subjects, with a mean age range at diagnosis of 1-60 years. At diagnosis, all patients revealed a variety of nonspecific symptoms, including cough, nasal congestion, arthralgia, fatigue, ecchymosis, and fever.
At diagnosis, most patients showed moderate to marked leukocytosis There were 190 cases in which it was agreed that the morphologic diagnosis was FAB M3 (either hypergranular form or variant form). [16, 17] Of these, 142 cases showed confirmed APL and responded to ATRA. Of these cases, 101 revealed t (15;17) . Of the remaining 89 cases, six was positive fusion product PML/RARα and five cases showed a t(11;17). The Other additional chromosomal abnormalities detected were del 8q, add 15q, +10, and ins [1q] .
Furthermore, in this study, 15 patients showed additional chromosomal abnormalities in addition to t(15;17), as shown in Table 2 . Trisomy 8 was the most frequent additional abnormality. [20] This study also presented 6 cases with trisomy 8, followed by 4 cases of i[17q], as the most frequent additional abnormality.
Discussion
APL is characterized by a proliferation of abnormal promyelocytic. The disease comprises about 5% to 10% of all AMLs [21] and is divided into the classic (hypergranular) and microgranular (hypogranular) types. The classic form of APL is characterized by t(15;17)(q22;12) or the presence of the PML/RARα transcript. Three alternative translocations associated with APL also have been characterized: t(11;17) (q23;q21) (PLZF/RARα), t(5;17)(q35;q21) (NPM/RARα), and t(11;17)(q13;q21) (NuMA/RARα). [22] Because patients with APL benefit from treatment with retinoid or arsenic compound therapy [23, 24] and have an increased risk of DIC and hemorrhage, the correct classification of APL is important. Definitive diagnosis is based on cytogenetic and molecular tests; these studies are highly technical and expensive, and results, often, are not available in a timely manner. Pathologists often are faced with the dilemma of classifying APL based only on morphologic, cytochemical, and immunophenotypic findings. Our study confirms that there is considerable difficulty distinguishing AML-M3v from APL-like leukemia based on these parameters.
Because morphologic, cytochemical, and immunophenotypic studies, often, are nonspecific in these leukemias, cytogenetic studies are necessary for accurate classification. Cytogenetically detectable rearrangements are identified remaining 48 cases showed AML-M3-like leukemia. These 48 patients revealed chromosomal abnormalities as shown in Table 1 . In this study, in the absence of t(15;17) or PML/RARα on FISH, 13.4% (32 cases) were diagnosed to be in remission with karyotype 46, XY or 46, XX.
One case showed del 16q and was diagnosed as AML M4 as patients with inv/del(16) (p13q22)/del(16) (q22)/t(16;16) (p13;q22) usually correspond to the subclass of AML M4, with a specific abnormal eosinophil component and is considered as a distinct entity in correlation with these specific chromosomal abnormalities. These cases of AML M4 are referred as AML M4E0. [19] in about 70% to 80% of cases. [25] In this study t(15;17) was detected in 53.1% cases that correlated with morphological and immunophenotypic diagnosis of APL. Additional studies such as FISH or RT-PCR may increase detectability of the translocation or transcript to almost 90% of cases. [26] Sainty et al. [27] undertook a morphologic, immunophenotypic, cytogenetic, and molecular review of a series of cases referred to as APL lacking t(15;17) and compared them with a control group of cases of APL with t(15;17). The majority of the APL cases that did not demonstrate t(15;17) revealed underlying rearrangements of the PML/RARα transcript by FISH or RT-PCR. [27] 
Conclusion
Our study shows that many other chromosomal abnormalities other than t(15;17) can show a similar morphol ogic, cytochemical, and immunophenotypic characteristics of APL. In such cases, karyotype analysis, FISH, and RT-PCR must be conducted to rule out APL. This APL-like cases constitute a heterogeneous group of population. The strength of the study is that cytogenetic was useful to detect 50%-55% cases of morphologic APL, which was strengthened by molecular study up to 80%-90%. But limitation of this study is that there is a considerable difficulty distinguishing AML-M3v from APL-like leukemia based on the morphological and cytochemical parameters.
